Friday, October 19, 2018 1:23:13 PM
Edwin M Horwitz..Pluristem Stockholder
Disclosure of Potential Conflicts of Interest
M.D. discloses Advisory role and stock ownership in
Rigenerand srl. C.B. discloses intellectual and ownership interest in LYST Therapeutics, Pall Corporation and research funding from Gunze Limited. E.M.H. discloses honorarium from Current Stem Cell Reports (journal) for service as Section Editor and stock ownership in Pluristem Therapeutics, Inc. The other authors indicated no potential conflicts of interest.
Intratumoral Delivery of Interferon?-Secreting Mesenchymal Stromal Cells Repolarizes Tumor-Associated Macrophages and Suppresses Neuroblastoma Proliferation In Vivo
https://stemcellsjournals.onlinelibrary.wiley.com/doi/10.1002/stem.2801
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM